Pharmafile Logo
Pharmafocus logo
Advanced Search

GSK

Showing 15 posts of 760 posts found.

Diabetes trial disappointment for GSK and Tolerx

March 14, 2011
Research and Development DEFEND-1, DEFEND-2, GSK, GlaxoSmithKline, Tolerx, diabetes, otelixizumab, type I diabetes

GSK and Tolerx’s type I diabetes drug otelixizumab has failed to meet its primary endpoint in a late-stage trial. Anti-CD3 …

News
systemic lupus erythematosus (SLE)

US approval for GSK’s lupus treatment Benlysta

March 10, 2011
Sales and Marketing Benlysta, GSK, GlaxoSmithKline, Human Genome Sciences, Lupus, belimumab, systemic lupus erythematosus

GlaxoSmithKline’s lupus treatment Benylsta has won an historic approval in the US, but will have to prove its safety record …

News
GlaxoSmithKline's London headquarters

GSK ends neuroscience research alliance

March 7, 2011
Research and Development GSK, GlaxoSmithKline, Targacept, neuronal nicotinic receptors, neuroscience research

GlaxoSmithKline has severed a strategic alliance formed in July 2007 with US biopharma company Targacept. GSK forked out $45 million …

News

GSK adds former Merck CFO to board

March 7, 2011
Sales and Marketing GSK, GlaxoSmithKline, Judy Lewent, Stacey Cartwright, appointment, sales and marketing

GlaxoSmithKline has appointed Judy Lewent to its board as a non-executive director. She has previously served as an executive VP …

Appointment
GlaxoSmithKline's London headquarters

GSK to reimburse tuition fees for UK trainees

March 3, 2011
Business Services, Research and Development, Sales and Marketing GSK, GlaxoSmithKline, UK science, careers, graduate, graduate recruitment

GlaxoSmithKline is set to reimburse UK university tuition fees paid by its trainees from 2012. Each year, GSK recruits between …

News

GlaxoSmithKline seeks alliances with ‘academic superstars’

March 2, 2011
Research and Development GSK, GlaxoSmithKline, Pentraxin Therapeutics, academia, al Free and University College Medical School, universities

GlaxoSmithKline has unveiled a partnership with a ‘superstar academic’, as part of a new strategy which it believes will help …

News
viiv_gsk_pfizer_david_redfern

David Redfern appointed ViiV chairman

February 28, 2011
Research and Development, Sales and Marketing David Redfern, GSK, GlaxoSmithKline, Pfizer, ViiV, ViiV Healthcare, appointment, research and development, sales and marketing

David Redfern has been appointed as chairman of ViiV Healthcare, the joint GlaxoSmithKline-Pfizer venture focused on HIV.

Appointment
Roche's Avastin (bevacizumab)

NICE yes for Votrient, no to Avastin

February 23, 2011
Sales and Marketing Cancer, GSK, GlaxoSmithKline, Kidney cancer, NICE, Roche, avastin, bevacizumab, breast cancer

NICE has recommended GlaxoSmithKline’s kidney cancer drug Votrient on the same day it gave a final negative decision to Roche’s …

News
GSK's swine flu vaccine Pandemrix

WHO wants narcolepsy link with swine flu vaccine investigated

February 10, 2011
Research and Development, Sales and Marketing Finland Institute, GSK, GlaxoSmithKline, Pandemrix, narcolepsy, swine flu

The World Health Organisation has called for further investigation into GSK’s swine flu vaccine link to sleeping disorder narcolepsy, following …

News

GSK profits slump amid ongoing Avandia woes

February 7, 2011
Sales and Marketing 2010 pharma results, Avandia, GSK, GlaxoSmithKline

GlaxoSmithKline’s ongoing woes with diabetes drug Avandia hit profits in 2010. Profits after tax plummeted 56% to £3 billion for …

News

GSK settles Avandia case out of court

February 1, 2011
Sales and Marketing Avandia, GSK, diabetes

GlaxoSmithKline this week settled a US federal lawsuit regarding its diabetes drug Avandia before it went to court. The company …

News

GSK and Actelion drop insomnia treatment

January 30, 2011
Research and Development Actelion, GSK, insomnia

Actelion and GlaxoSmithKline are to abandon development of phase III insomnia drug almorexant because of problems with side-effects.Almorexant a dual …

News
GlaxoSmitKline's headquarters

GSK skin cancer drugs moves into phase III

January 25, 2011
Research and Development BRAF V600 mutation, Cancer, Duchenne Muscular Dystrophy, GSK, GSK1120212, GSK2118436, GSK968, GlaxoSmithKline, melanoma, skin cancer

GlaxoSmithKline has begun late-stage trials of two new drugs for advanced or metastatic melanoma patients. GSK2118436 and GSK1120212 are being …

News

GSK takes £2.2bn hit from Avandia claims

January 18, 2011
Sales and Marketing Avandia, GSK, GlaxoSmithKline, rosiglitazone

GlaxoSmithKline’s Avandia woes are continuing, with the company admitting it expects to take a mammoth legal charge over the troubled …

News

Anti-cancer stem cell drug starts clinical trials

January 14, 2011
Research and Development Cancer, GSK, GlaxoSmithKline, OMP-21M18, OMP-59R5, OncoMed, Stem cells, advanced solid tumour cancers

OncoMed and GSK’s novel anti cancer stem cell drug OMP-59R5 has begun clinical trials and could represent the future direction …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025